IP Library Granted Patent US 12662456
Granted Patent B2
US 12662456 · App. 18/655,883 · Granted Jun 23, 2026

Dextrorphan prodrugs and processes for making and using them

Inventors: Travis Mickle (Celebration, FL); Sven Guenther (Coralville, IA); Sanjib Bera (Blacksburg, VA)
Assignee: Zevra Therapeutics, Inc.
C07D221/28A61K47/542
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662456
App. No.
18/655,883
Granted
Jun 23, 2026
Kind
B2
Abstract

The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of levorphanol.

Claims (32)

1 . A compound having the following general formula:

where L 1 is

and L 2 is absent, or

Y 1 and Y 2 are independently either absent, or [A-X—Z] n

where A and Z are independently selected for Y 1 and Y 2 , and are, independent of each other, either absent or selected from —O—, —S—, or —(CR 1 R 2 ) k —,

and where X is —(CR 1 R 2 )—;

J is [M-W] p

where M is —(CR 3 R 4 ) q —; and W is absent, or —O— or —S—

R 1 and R 2 are each independently selected for Y 1 and Y 2 , and are, independent of each other, selected from H, alkyl, aryl, alkylaryl, alkoxy, haloalkyl, or haloaryl

R 3 and R 4 are each independently selected from H, alkyl, aryl, alkylaryl, alkoxy, haloalkyl, or haloaryl

for each Y 1 and Y 2 , n is independently an integer of 1-4

for each repeating unit of [A-X—Z] n , when —(CR 1 R 2 ) k — is present, k is independently an integer of 1-4,

p and q are independently selected from 1-4

G 1 m and G 2 m are independently absent, or selected independently of each other and, when present, each repeating subunit is independently selected from H, oxoacid, polyethylene glycol having from 2 to 5 ethylene oxide units, or a vitamin compound;

where m is selected independently for G 1 and G 2 , and is an integer of 1-4, except that m is 1 when G 1 or G 2 is a hydrogen atom;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein at least one of G 1 and G 2 is at least one oxoacid.

3 . The compound of claim 2 , wherein G 1 and G 2 are each acetic acid.

4 . The compound of claim 1 , wherein the compound is 3-acetyl-N-(acetyl-OCH 2 )-dextrorphanium having the following structural formula:

or a pharmaceutically acceptable salt thereof.

5 . A composition wherein the composition comprises the compound of claim 1 or a pharmaceutically acceptable salt of the compound.

6 . A composition wherein the composition comprises the compound of claim 4 or a pharmaceutically acceptable salt of the compound.

7 . The composition of claim 5 , wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, i-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, l-tartrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate, or combinations thereof.

8 . The composition of claim 6 , wherein the pharmaceutically acceptable salt is selected from the group consisting of acetate, l-aspartate, besylate, bicarbonate, carbonate, d-camsylate, l-camsylate, citrate, edisylate, formate, fumarate, gluconate, hydrobromide/bromide, hydrochloride/chloride, d-lactate, i-lactate, d,l-lactate, d,l-malate, l-malate, mesylate, pamoate, phosphate, succinate, sulfate, bisulfate, d-tartrate, l-tartrate, d,l-tartrate, meso-tartrate, benzoate, gluceptate, d-glucuronate, hybenzate, isethionate, malonate, methylsulfate, 2-napsylate, nicotinate, nitrate, orotate, stearate, tosylate, thiocyanate, acefyllinate, aceturate, aminosalicylate, ascorbate, borate, butyrate, camphorate, camphocarbonate, decanoate, hexanoate, cholate, cypionate, dichloroacetate, edentate, ethyl sulfate, furate, fusidate, galactarate (mucate), galacturonate, gallate, gentisate, glutamate, glutarate, glycerophosphate, heptanoate (enanthate), hydroxybenzoate, hippurate, phenylpropionate, iodide, xinafoate, lactobionate, laurate, maleate, mandelate, methanesulfonate, myristate, napadisilate, oleate, oxalate, palmitate, picrate, pivalate, propionate, pyrophosphate, salicylate, salicylsulfate, sulfosalicylate, tannate, terephthalate, thiosalicylate, tribrophenate, valerate, valproate, adipate, 4-acetamidobenzoate, camsylate, octanoate, estolate, esylate, glycolate, thiocyanate, undecylenate, or combinations thereof.

9 . The composition of claim 5 , wherein the compound is present in an amount of about 0.5 mg or higher.

10 . The composition of claim 6 , wherein the compound is present in an amount of about 0.5 mg or higher.

11 . The composition of claim 5 , wherein the compound is provided in a dosage form selected from the group consisting of a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, a syrup, an oral film, a thin strip, a slurry, and a suspension.

12 . The composition of claim 6 , wherein the compound is provided in a dosage form selected from the group consisting of a tablet, a capsule, a caplet, a suppository, a troche, a lozenge, an oral powder, a solution, a syrup, an oral film, a thin strip, a slurry, and a suspension.

13 . The composition of claim 5 , wherein the composition comprises at least one additional active substance.

14 . The composition of claim 13 , wherein the at least one additional active substance is selected from the group consisting of a different dextrorphan conjugate or unconjugated dextrorphan.

15 . The composition of claim 14 , wherein the at least one additional active substance is a different dextrorphan conjugate.

16 . The composition of claim 14 , wherein the at least one additional active substance is unconjugated dextrorphan.